Literature DB >> 21229043

Contemporary Management of Bladder Cancer: Identifying patients who are at risk.

D Bell, Y Fradet.   

Abstract

Bladder cancer is currently the fifth most common cancer in Western society, and its incidence appears to be increasing. Important advances have recently occurred in both diagnostic and therapeutic approaches to bladder neoplasms. Presentation is not unique, and physician awareness is important to identify patients who are at risk for bladder neoplasia and consequently require further investigation. A diagnostic approach and contemporary management are discussed.

Entities:  

Year:  1991        PMID: 21229043      PMCID: PMC2145394     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  16 in total

1.  Treatment of diffuse transitional cell carcinoma in situ by whole bladder hematoporphyrin derivative photodynamic therapy.

Authors:  R C Benson
Journal:  J Urol       Date:  1985-10       Impact factor: 7.450

2.  A newer form of bladder substitute based on historical perspectives.

Authors:  U E Studer; D Ackermann; G A Casanova; E J Zingg
Journal:  Semin Urol       Date:  1988-02

3.  The impact of cigarette smoking on stage, grade and number of recurrences of transitional cell carcinoma of the bladder.

Authors:  I M Thompson; M Peek; F R Rodriguez
Journal:  J Urol       Date:  1987-03       Impact factor: 7.450

4.  M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

Authors:  C N Sternberg; A Yagoda; H I Scher; R C Watson; H W Herr; M J Morse; P C Sogani; E D Vaughan; N Bander; L R Weiselberg
Journal:  J Urol       Date:  1988-03       Impact factor: 7.450

5.  Polymorphic expression of a human superficial bladder tumor antigen defined by mouse monoclonal antibodies.

Authors:  Y Fradet; N Islam; L Boucher; C Parent-Vaugeois; M Tardif
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 6.  The biology and treatment of superficial bladder cancer.

Authors:  F M Torti; B L Lum
Journal:  J Clin Oncol       Date:  1984-05       Impact factor: 44.544

7.  Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors.

Authors:  A Morales; D Eidinger; A W Bruce
Journal:  J Urol       Date:  1976-08       Impact factor: 7.450

8.  Toxicity of intravesical BCG and its management in patients with superficial bladder tumors.

Authors:  E Orihuela; H W Herr; C M Pinsky; W F Whitmore
Journal:  Cancer       Date:  1987-08-01       Impact factor: 6.860

9.  Superficial bladder cancer: progression and recurrence.

Authors:  N M Heney; S Ahmed; M J Flanagan; W Frable; M P Corder; M D Hafermann; I R Hawkins
Journal:  J Urol       Date:  1983-12       Impact factor: 7.450

10.  Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder.

Authors:  G R Prout; C W Lin; R Benson; U O Nseyo; J J Daly; P P Griffin; J Kinsey; M E Tian; Y H Lao; Y Z Mian
Journal:  N Engl J Med       Date:  1987-11-12       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.